- Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC 📹 Bloomberg — · 15min
- Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC Bloomberg —
- Pfizer CEO on AI-designed molecule, and race to use new tech 📹 Bloomberg — · 1min
- Pfizer expects $59.5B-$62.5B 2026 revenue, cites post-2028 high single-digit CAGR visibility after Vyndamax settlement Seeking Alpha —
- Pfizer's newer drugs pushed earnings past Wall Street expectations Quartz —
- Pfizer Posts Better-Than-Expected Revenue, Profit Wall Street Journal —
- Pfizer beats Q1 profit estimates on older drugs demand RTE —
- Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending Wall Street Journal —
- Pfizer in charts: Specialty Care, Oncology and Biosimilars drive Q1 growth, offsetting Primary Care decline Seeking Alpha —
- Earnings Snapshot: Pfizer beats Q1 estimates but misses guidance Seeking Alpha —
- Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth CNBC —
Albert Bourla
Greek-American pharmaceutical executive
Albert Bourla is a Greek-American veterinarian and businessman known for serving as the chairman and chief executive officer of the pharmaceutical company Pfizer. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla was chief operating officer.
Also known as...
A. Bourla
Pfizer beats Q1 earnings estimates